Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543845 | 0.79 | ELANE (0.34) | ALDH1A1ELANE | |
| SCHEMBL544423 | 0.76 | ELANE (0.35) | ALDH1A1NR3C1MEN1KMT2AELANE | |
| Hydrochloric Acid SCHEMBL892604 | 0.75 | ELANE (0.33) | ALDH1A1ELANE | |
| SCHEMBL544345 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHRMEN1KMT2AELANE | |
| SCHEMBL12158612 | 0.73 | NR3C1 (0.35) | PTPN1ALDH1A1GRIN2BNR3C1MEN1 | |
| SCHEMBL544088 | 0.73 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL543963 | 0.69 | PTPRC (0.34) | MEN1KMT2A | |
| SCHEMBL892564 | 0.69 | PDE4A (0.36) | ALDH1A1TSHRGAA | |
| SCHEMBL893095 | 0.67 | ELANE (0.35) | ELANE | |
| SCHEMBL15803164 | 0.64 | ELANE (0.35) | ALDH1A1TSHRNR3C1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| EP-1219621-B1 | AZAINDOLIZINONE DERIVATIVES AND COGNITIVE ENHANCERS COMPRISING THE SAME AS EFFECTIVE COMPONENTS | ZENYAKU KOGYO KK (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6635652-B1 | Senile dementia and Alzheimer's disease | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-10-21 | — | — | US | disclosed |
| EP-1219621-A1 | AZAINDOLIZINONE DERIVATIVES AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, GRN | PTPN1 4068/4885ALDH1A1 116/4885CYP1A2 415/4885 |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | PTPN1 4730/4885ALDH1A1 159/4885CYP1A2 592/4885 |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | PSEN1, GAP43, PSEN2 | PTPN1 4751/4885ALDH1A1 905/4885CYP1A2 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.